Global Inflammatory Bowel Diseases Market
市场规模（十亿美元）
CAGR :
% 
USD
22.42 Billion
USD
33.88 Billion
2023
2031
 Forecast Period |
2024 –2031 |
 Market Size (Base Year) |
USD 22.42 Billion |
 Market Size (Forecast Year) |
USD 33.88 Billion |
 CAGR |
% |
| Major Markets Players |
|
Global Inflammatory Bowel Diseases Market Segmentation, By Type (Microscopic Colitis, Ulcerative Colitis, and Crohn's Disease), Treatment (Medication, Surgery, and Others), Dosage Form (Tablet, Capsule, Injections, and Others), Route of Administration (Oral, Parenteral, and Others), Diagnosis (Imaging Procedures, Endoscopic Procedures, and Lab Tests), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031
Inflammatory Bowel Diseases Market Analysis
The inflammatory bowel diseases market is witnessing significant growth, driven by increasing prevalence rates and advancements in treatment options. IBD, which includes Crohn's disease and ulcerative colitis, affects millions worldwide, prompting a surge in demand for effective therapies and diagnostic tools. Recent developments highlight the emergence of biologics and biosimilars, which offer targeted treatments that improve patient outcomes. Additionally, the growing emphasis on personalized medicine is reshaping the landscape, as healthcare providers seek to tailor therapies based on individual patient profiles. Moreover, increasing awareness and education around IBD are leading to early diagnosis and treatment initiation, further propelling market growth. As a result, key players are investing in research and development to introduce innovative solutions, addressing the unmet needs of patients and enhancing the overall quality of care in this dynamic market.
Inflammatory Bowel Diseases Market Size
The global inflammatory bowel diseases market size was valued at USD 22.42 billion in 2023 and is projected to reach USD 33.88 billion by 2031, with a CAGR of 5.30% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Inflammatory Bowel Diseases Market Trends
“Rise of Biologics and Biosimilars”
炎症性肠病市场正在迅速发展，其特点是创新治疗方法和加强的患者管理策略。一个值得注意的趋势是生物制剂和生物仿制药的兴起，它们为克罗恩病和溃疡性结肠炎等疾病提供针对性治疗。与传统疗法相比，这些进步提高了治疗效果并减少了副作用。此外，远程医疗和移动健康应用等数字健康技术的整合正在重塑患者参与和监测。这一趋势使患者和医疗保健提供者之间能够更好地沟通，从而促进及时干预。随着对 IBD 的认识和研究不断增长，市场预计将大幅扩张，为患者和医疗保健专业人士提供新的机遇。
报告范围和炎症性肠病市场细分
|
属性 |
炎症性肠病关键市场洞察 |
|
涵盖的领域 |
|
|
覆盖国家 |
北美洲的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、巴西、阿根廷和南美洲其他地区 |
|
主要市场参与者 |
辉瑞公司（美国）、葛兰素史克公司（英国）、诺华公司（瑞士）、Viatris 公司（美国）、梯瓦制药工业有限公司（以色列）、赛诺菲（法国）、阿斯利康（英国）、强生私人有限公司（美国）、默克公司（美国）、罗氏公司（瑞士）、百特（美国）、拜耳公司（德国）、礼来公司（美国）、太阳制药工业有限公司（印度）、Aurobindo Pharma（印度）、Lupin（印度）、艾伯维公司（美国）、雅培（美国）、博士伦制药公司（加拿大） |
|
市场机会 |
|
|
增值数据信息集 |
除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察之外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。 |
炎症性肠病市场定义
炎症性肠病是指一组胃肠道慢性炎症性疾病，主要包括克罗恩病和溃疡性结肠炎。这些疾病的特征是消化道内壁发炎，导致腹痛、腹泻、体重减轻和炎症性肠病疲劳等症状。炎症性肠病的确切病因尚不清楚，但据信涉及遗传、环境和免疫系统因素的综合作用。这些疾病会严重影响患者的生活质量，可能需要通过药物、生活方式改变以及在某些情况下进行手术进行长期治疗。
炎症性肠病市场动态
驱动程序
- 炎症性肠病患病率上升
全球范围内炎症性肠病的发病率和患病率不断上升，极大地刺激了对有效治疗和诊断工具的需求。随着越来越多的人被诊断出患有克罗恩病和溃疡性结肠炎等疾病，迫切需要能够缓解症状和改善患者预后的创新疗法。患者人数的不断增长促使制药公司和医疗保健提供商专注于开发先进的药物和诊断技术。此外，公众和医疗保健专业人员对炎症性肠病的认识不断提高，从而导致更早的诊断和治疗干预，进一步推动市场增长并扩大必要医疗保健解决方案的可用性。
- 认知度和诊断水平不断提高
新兴经济体医疗基础设施的改善和先进医疗设施的普及在增强炎症性肠病患者管理和治疗方案方面发挥着至关重要的作用。随着这些地区投资于现代医疗系统，患者能够更好地获得专业护理、诊断服务和创新治疗模式。这一发展确保及时干预，并为持续管理克罗恩病和溃疡性结肠炎等慢性病营造更有利的环境。随着设施的改善，医疗保健提供者可以提供全面的护理，包括提高治疗效果的多学科方法，最终有助于改善患者治疗效果并推动炎症性肠病市场的增长。
机会
- 远程医疗与数字健康的融合
远程医疗和数字健康技术的融合为增强炎症性肠病患者参与度、监测和管理提供了良好的机会。通过利用远程咨询、移动健康应用程序和可穿戴设备，医疗服务提供者可以与患者保持持续沟通，从而及时干预和个性化护理。这些技术有助于定期跟踪症状和坚持服药，从而带来更好的健康结果。此外，它们还使患者能够积极参与治疗过程，从而更好地了解自己的病情。随着医疗系统越来越多地采用这些数字解决方案，它们创造了一种更加以患者为中心的方法，从而提高了治疗依从性，并提高了炎症性肠病患者的整体生活质量。
- 研究与开发
持续投资于新型疗法和个性化医疗方法的研究和临床试验，为解决炎症性肠病治疗中尚未满足的需求提供了巨大的机会。随着对克罗恩病和溃疡性结肠炎等疾病病理生理学的理解不断加深，对迎合个体患者特征的创新疗法的需求日益增加。通过专注于个性化医疗，研究人员可以开发出针对性的治疗方法，以优化疗效，同时最大限度地减少副作用。此外，临床试验为可能提供长期缓解甚至潜在治愈的疗法突破铺平了道路。这种对研究的持续投入增强了治疗选择，并促进了一个充满活力且反应迅速的市场，有望实现大幅增长。
限制/挑战
- 治疗的副作用
许多现有的炎症性肠病治疗方法都伴有显著的副作用，这对有效的疾病管理构成了严峻挑战。患者经常会出现胃肠不适、疲劳或免疫系统抑制等不良反应，导致治疗中断或不遵守规定的治疗方案。这增加了疾病管理的复杂性，增加了疾病发作和长期并发症的风险。因此，医疗保健提供者面临着一项艰巨的任务，即平衡治疗的潜在益处和副作用的风险。这一挑战凸显了持续研究更安全、更有效的治疗方法的必要性，以最大限度地减少副作用并提高患者的依从性。
- 生物药物成本高昂
生物药物和先进疗法的高成本对治疗的可及性构成了重大障碍，特别是对于发展中国家的患者而言。生物制剂通常是治疗中度至重度炎症性肠病的必需品，但价格昂贵，许多个人和资源有限的医疗保健系统都负担不起。这种经济负担限制了这些疗法的可及性，导致患者只能依赖效果较差或过时的治疗方法。因此，发达地区和发展中地区之间的医疗质量差距越来越大，严重制约了全球市场的增长，并限制了患者获得尖端治疗的机会。
本市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需获取更多市场信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
炎症性肠病市场范围
市场根据类型、治疗、剂型、给药途径、诊断、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 显微镜结肠炎
- 溃疡性结肠炎
- 克罗恩病
治疗
- 药物
- 外科手术
- 其他的
剂型
- 药片
- 胶囊
- 注射
- 其他的
给药途径
- 口服
- 肠外
- 其他的
诊断
- 影像学检查
- 内窥镜检查
- 实验室测试
最终用户
- 医院
- 专科诊所
- 家庭护理
- 其他的
分销渠道
- 医院药房
- 零售药店
- 网上药店
- 其他的
炎症性肠病市场区域分析
对市场进行分析，并按国家、类型、治疗、剂型、给药途径、诊断、最终用户和分销渠道提供市场规模洞察和趋势，如上所述。
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America leads the inflammatory bowel diseases market in terms of revenue and market share, a trend expected to continue throughout the forecast period. This dominance is driven by increasing demand for specialized treatments, rising healthcare expenditures, and a high prevalence of conditions such as ulcerative colitis and Crohn's disease. The presence of key industry players further supports market growth in this region.
Asia-Pacific is projected to be the fastest-growing region in the inflammatory bowel diseases market from 2024 to 2031, driven by increasing disposable income and improved healthcare infrastructure. Rising government initiatives aimed at enhancing healthcare services will further accelerate market growth in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Inflammatory Bowel Diseases Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Inflammatory Bowel Diseases Market Leaders Operating in the Market Are:
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Viatris Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Baxter (U.S.)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- AbbVie Inc. (U.S.)
- Abbott (U.S.)
- Bausch Health Companies Inc. (Canada)
Latest Developments in Inflammatory Bowel Diseases Market
- In May 2024, Johnson & Johnson Services Inc. announced the phase 3 results of its Crohn's disease program for Tremfya. The trial data showed that Tremfya outperformed Stelara in all endoscopic patients within the study group, highlighting its superior efficacy. This marks a significant advancement in Crohn's disease treatment
- In April 2024, Takeda Pharmaceutical Company Limited received FDA approval for subcutaneous administration of Entyvio following initial IV induction therapy. Entyvio is used to treat patients with severely active Crohn’s disease, offering a more convenient treatment option post-induction
- In October 2023, Johnson & Johnson Services, Inc. released phase 3 clinical trial data for Tremfya (guselkumab), evaluating its safety and efficacy for active ulcerative colitis. The study showed a 77% overall clinical response rate, with early symptom improvement observed in patients. This highlights Tremfya's potential as a treatment for ulcerative colitis
- In June 2023, Lilly's Omvoh (mirikizumab) gained market authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for treating ulcerative colitis. This approval marks an important step in expanding treatment options for patients with the condition
- In February 2023, AbbVie announced that the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) approved RINVOQ, a JAK inhibitor, for treating moderate to severe Crohn's disease. This approval is for patients who did not respond adequately to conventional therapies
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
